Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
Clinical trial NCT05879107 · COMPLETED
Trial details
- NCT number
- NCT05879107
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-26
- Primary completion
- 2023-12-06
- Enrollment
- 1113
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.